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Abstract
Cancer diagnosis at an early stage increases the chance of curative treatment and of survival. It has 
been suggested that delays on the pathway from first symptom to diagnosis and treatment may be 
socio-economically patterned, and contribute to socio-economic differences in receipt of treatment 
and in cancer survival.
This review aimed to assess the published evidence for socio-economic inequalities in stage at 
diagnosis of lung cancer, and in the length of time spent on the lung cancer pathway. MEDLINE, 
EMBASE and CINAHL databases were searched to locate cohort studies of adults with a primary 
diagnosis of lung cancer, where the outcome was stage at diagnosis or the length of time spent 
within an interval on the care pathway, or a suitable proxy measure, analysed according to a 
measure of socio-economic position. Meta-analysis was undertaken when there were studies 
available with suitable data.
Of the 461 records screened, 39 papers were included in the review (20 from the UK) and seven in 
a final meta-analysis for stage at diagnosis. There was no evidence of socio-economic inequalities 
in late stage at diagnosis in the most, compared to the least, deprived group (odds ratio=1.04, 95% 
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confidence interval = 0.92 to 1.19). No socio-economic inequalities in the patient interval or in 
time from diagnosis to treatment were found.
Socio-economic inequalities in stage at diagnosis are thought to be an important explanatory factor 
for survival inequalities in cancer. However, socio-economic inequalities in stage at diagnosis were 
not found in a meta-analysis for lung cancer.
Keywords
Lung cancer; socio-economic inequalities; interval; time; stage
Background
Cancer patients who are diagnosed at an early stage are more likely to be suitable for receipt 
of potentially curative treatment, thus improving their chances of survival. Length of time to 
diagnosis and treatment has also been associated with cancer survival (1). Delays may lead 
to diagnosis at a later disease stage, resulting in ‘potentially-avoidable’ deaths (2). To 
address this, the National Awareness and Early Diagnosis Initiative (NAEDI) scheme was 
launched in England, in order to encourage early presentation of patients to primary care and 
to improve general practitioner (GP) cancer recognition and referral (2).
Lung cancer is the most common cancer, worldwide. In the USA and the UK it is the second 
most incident cancer (3, 4), as well as the most common cause of cancer mortality (4, 5). In 
the UK fewer than 10% of those diagnosed with lung cancer survive for 5 years (6).
A socio-economic gradient for lung cancer survival (7) exists in the UK, which is not fully 
accounted for by the socio-economic gradient in incidence. Socio-economic inequalities in 
receipt of lung cancer treatment have been shown in a recent systematic review and meta-
analysis (8) and there is some evidence that inequalities in treatment contribute to socio-
economic inequalities in lung cancer survival (9, 10). It has also been suggested that 
inequalities in stage at diagnosis and in time to diagnosis and treatment might contribute to 
socio-economic differences in cancer survival (2). However, there has been no systematic 
examination of whether there are socio-economic inequalities in stage at diagnosis and time 
to treatment for lung cancer and where on the pathway from symptom-onset to treatment 
these inequalities might arise.
This review aimed to investigate whether there are socio-economic inequalities in stage at 
diagnosis for lung cancer, and in the duration of intervals (patient, primary care, referral, 
diagnosis, treatment) on the diagnostic and treatment pathway.
Methods/Design
A protocol was developed, registered with PROSPERO (11) and published (12). Systematic 
methods were used to identify relevant studies, assess study eligibility for inclusion and 
evaluate study quality. The review is reported according to the Preferred Reporting Items for 
Systematic Reviews and Meta-Analyses (PRISMA) guidelines (13) (see Appendix S1 for 
PRISMA checklist).
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Search strategy
A search was undertaken to locate all studies published by the initial search date (Jan 2014), 
with a title and abstract published in English, examining differences, by socio-economic 
position (SEP), in stage at diagnosis and in patient, primary care, referral, diagnostic and 
treatment time intervals (and combinations thereof) on the care pathway for lung cancer. The 
searches were re-run in Feb 2016 and any further studies retrieved for inclusion.
One researcher (LF) developed the search strategy (File S2), which was refined with the help 
of an Information Scientist and used to search the online databases of MEDLINE, EMBASE 
and CINAHL. The search terms were adapted for the different databases. Additional studies 
were identified by reviewing the reference lists of all included studies and by using a 
forward citation search to identify more recent studies that had cited included studies. 
EndNote X5 software was used to manage the references.
Study Eligibility
The following types of study were deemed eligible for inclusion: cohort studies of adult 
participants who had a primary diagnosis of lung cancer (small-cell lung cancer or non-
small-cell lung cancer - ICD10 C 33 C34); published in a peer-reviewed journal up to the 
date that the search was run and where the outcome was:
• Stage at diagnosis or stage at the start of treatment (14) [primary outcome]
• OR mean or median time within an interval on the pathway from first symptom 
to treatment (or a suitable proxy measure of this); Or the likelihood (odds 
ratio[OR] or hazard ratio [HR] with 95% confidence intervals [CI]) of longer or 
shorter time within an interval on the pathway [secondary outcome];
• And where outcome was analysed by a measure of SEP (an individual or area-
based measure of deprivation, poverty, income or education).
Time interval definition
The following four time points have been identified as important markers on the cancer 
pathway: date of first symptom onset, date of first presentation to a health care professional, 
date of referral to secondary/specialist care and date of diagnosis (15). These and other time 
points such as date of first secondary (specialist) care investigation/first hospital 
appointment, and date of first treatment can be used to define 15 interim time intervals 
(designated T1-T15) on the pathway from first symptom to diagnosis and treatment (16).
These time intervals can be categorised as follows: patient interval (time from date of first 
symptom to date of first presentation; T1); primary care interval (date of first presentation to 
date of first investigation referral; T6); referral interval (date of GP referral to first specialist 
appointment or investigation; T10); diagnostic interval (date of secondary care investigation 
to diagnosis T13); and treatment interval (diagnosis to treatment; T15) (12), and 
combinations thereof.
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The following were included as potential proxy measures of length of time intervals on the 
pathway; type of referral (urgent v routine) (17); emergency presentation (18); diagnosis at 
death; and number of pre-referral consultations (19).
Stage definition
Lung cancer stage can be categorised as I, II, III, IV, assigned using the TNM staging system 
(20). Papers which recorded stage at diagnosis or stage at start of treatment in this way, or as 
early or late stage, or as local, regional and distant stage, were considered for inclusion in 
the stage analysis.
Study Selection and Data Extraction
Studies obtained from the database searches were independently assessed by two researchers 
(LF and SS) in three phases: title, abstract and full paper screening, as detailed in the 
protocol (12). Any disagreements at any of the screening stages were resolved by discussion 
between the two researchers in the first instance. A third reviewer (JA) was available to 
independently review the title, abstract or full paper, if required.
Data extraction was carried out by LF using a pro-forma based on previous work (8). Data 
from a random sample of 10% of included papers were checked by SS, selected using a 
random number generator.
Insurance status is an important factor relating to access to lung cancer care in the US 
healthcare system (21) and so may impact on time-intervals on the care pathway. Therefore, 
as in a previous lung cancer systematic review,(8) studies were split into three categories: 
those carried out in a healthcare system free at the point of access (a universal health care 
system (UHCS) similar to the UK); those based on an insurance system (similar to the 
USA); and those that include a mixture of free care and social insurance-based payment 
(some European systems).
Study Quality
A study quality checklist, adapted from existing quality tools (8, 15), was used to divide 
studies into eight quality categories, with 1 being the lowest, and 8 the highest quality 
(appendix S3).
Cohort studies reporting only univariable analysis are of lower quality, in terms of their 
ability to control for confounding. Only studies conducting multivariable analysis (quality 
scores 3-8) were considered for meta-analysis.
Statistical analysis
All studies that met the inclusion criteria were included in a narrative synthesis. Studies 
were analysed in three categories: stage at diagnosis, time interval (with sub-group analyses 
by interim intervals), and proxy time interval measures.
Studies were considered eligible for inclusion in meta-analysis if: multivariable analysis was 
conducted (and included control for a minimum of age and sex as confounders); OR/HRs 
and 95% CIs of likelihood of earlier or later stage at diagnosis or longer or shorter time 
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within an interval on the pathway (or a suitable proxy measure of this) in low compared to 
high SEP were calculated; and SEP was not further stratified by another variable. Sub-group 
analyses by healthcare system category were conducted if two or more comparable studies 
per system were available.
Random effects meta-analysis of eligible studies was undertaken using Cochrane 
Collaboration Review Manager 5.1. Natural logs of the ORs and their standard errors (SEs) 
were calculated for use in Forest plots. Where a study reported the most deprived class as the 
comparator then reverse ORs were calculated prior to meta-analysis. The I2 statistic was 
used to assess heterogeneity.
Multiple papers using the same or overlapping study data were considered for inclusion. 
Sensitivity analyses were undertaken to examine the effect of including all potentially-
eligible studies or only high quality studies in meta-analyses. However, only data from the 
better quality or more detailed paper in each overlapping study group were included in the 
final meta-analyses.
Results
A total of 39 papers (14, 18, 22–58) met the inclusion criteria (table S1) and were included 
in the review (PRISMA flow diagram, Figure 1). Twenty papers used data from the UK, 10 
from the USA, 2 from Canada, 2 from Denmark and 1 each from Sweden, Australia, Italy, 
Korea and New Zealand. Twenty nine papers used data from healthcare systems free at point 
of access and 10 from insurance-based systems. Of the 39 papers, 23 examined stage at 
diagnosis, 12 examined time intervals (three studies looked at both time intervals and stage 
at diagnosis), and eight examined potential proxy measures of delay. Some studies 
examining stage at diagnosis were suitable for meta-analysis.
Stage at diagnosis
Of the 23 studies that examined socio-economic inequalities in stage at diagnosis, 16 studies 
contained data that were unsuitable for meta-analysis (one reported ORs but examined SEP 
subdivided by race, one calculated univariable ORs, and 14 did not calculate odds ratios - 
nine presented unadjusted rates (five with statistical tests) and five presented no numbers 
(table S4). Of these 16 studies, 12 reported or appeared to show no association, and 3 
reported an association between SEP and stage at diagnosis, but not all in the same direction. 
One Scottish study (28) found that rates of early stage cancer were higher in more deprived 
patients than less deprived. Similarly, a US study (54) found that college graduates were 
more likely to be diagnosed with advanced stage at diagnosis compared to those without a 
college degree, but income was not associated with stage. However, in contrast, a further US 
study (36) reported that a higher percentage of more deprived patients were diagnosed with 
later stage cancer (but no numbers presented).
Eight studies (nine outcomes) conducted multivariable analysis and examined the likelihood 
(OR) of later (or earlier stage) at diagnosis by a marker of SEP and so were considered for 
meta-analysis (table S5). Of these, two studies looked at the same population and one study 
looked at the same outcome using two different measures of SEP (education and income). 
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Seven studies (seven outcomes) with non-overlapping populations were selected for the final 
meta-analysis.
Overall, there was no evidence of socio-economic inequalities in late stage at diagnosis in 
the most, compared to the least, deprived groups (n=7, odds ratio=1.04, 95% confidence 
interval = 0.92 to 1.19) (Fig 2). In sub-group analysis by healthcare system, although there 
was no evidence of differences by SEP in UHCS, there was some suggestion that more 
deprived patients were likely to present with more advanced stage cancer in non-UHCS, 
although only 2 studies were included. Sensitivity analyses including all studies with 
overlapping populations, utilising a different measure of SEP, or different combinations of 
these, also found no association (appendix S6).
Time intervals
Twelve studies examined inequalities within eight of the 15 time intervals. No studies were 
found that examined the intervals from symptom onset to FHA (T3) or to treatment (T5) or 
from patient presentation to GP referral, FHA, diagnosis or treatment (T6-T9), or FHA to 
treatment (T14). Summary interval results are shown in Fig 3 and detailed results for each 
interval presented in supplementary tables 7-10.
Two studies examined the time from symptom recognition to presentation (T1 patient 
interval). Socioeconomic position was not associated with length of patient interval in any of 
these (table S7). The intervals from first symptom to GP referral (T2), and to diagnosis (T4), 
were examined in one study, and again no socio-economic inequalities in time intervals were 
found (table S7).
Two studies examined the referral interval (T10). One found socioeconomic inequalities in 
time from GP referral to FHA with more deprived patients less likely to have a FHA within 
14 days of referral, using cancer registry data. The other used self-reported patient survey 
data and no association between referral interval and SEP was found (table S8).
Four studies (10 outcomes) examined time from GP referral to diagnosis (T11; table S8). In 
one study, the more highly educated (2 outcomes) were less likely to have delayed diagnosis 
but no association was found with income (2 outcomes). The other good quality study found 
no association and the remaining two studies only reported univariable analyses and did not 
clearly report tests of statistical significance. One of these analysed data from early and late 
stage patients separately: more deprived early stage patients had longer time from referral to 
diagnosis than less deprived patients (32 compared to 17 days, although no formal statistical 
tests were reported). No difference in the time between referral to diagnosis between more 
and less deprived patients with late stage disease were found.
Two studies examined socioeconomic inequalities in time from GP referral to treatment 
(T12) but none were found (table S8).
Three studies examined time from FHA to diagnosis and none found an association with 
SEP (T13; table S9). Five studies (eight outcomes) examined socioeconomic inequalities in 
time from diagnosis to treatment (T15) but inequalities in the treatment interval were not 
found (table S10).
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Other measures
Eight studies looked at the following measures that might be considered as consequences of 
delay: acute presentation, emergency admission, number of times to consult, and diagnosis 
at death. More deprived patients were more likely to present and to be admitted as an 
emergency, but socio-economic inequalities were not found in number of times to consult or 
in diagnosis at death (table S11).
Discussion
Principal Findings
This is the first systematic review to explore socio-economic inequalities in stage at 
diagnosis and in duration of intervals on the diagnostic and treatment pathway of lung 
cancer. Thirty nine studies met the inclusion criteria, 23 examined stage at diagnosis (eight 
of which were suitable for meta-analysis), 12 examined time intervals, and eight examined 
proxy measures of delay. There was no evidence of socio-economic inequalities in late stage 
at diagnosis in the most, compared to the least, deprived group overall and in studies from 
countries with UHCSs. However, there was evidence that more deprived patients were more 
likely to present as emergencies. There was some suggestion of socio-economic inequalities 
in stage at diagnosis in studies from countries with non-UHCSs with those in more deprived 
groups more likely to be diagnosed at late stage than others. No evidence of socio-economic 
inequalities in the patient or treatment intervals were found, and no consistent pattern was 
observed in diagnostic or referral intervals. No studies examined the primary care interval.
Interpretation of results and comparison to previous findings
Surgery with curative intent is only suitable for early stage lung cancer patients (59) and if 
patients with lower SEP are more likely to present later, and with later stage disease, this 
may help explain known socioeconomic inequalities in receipt of lung cancer surgery (8). In 
this review, however, presentation with later stage lung cancer in more deprived patients was 
not seen and so inequalities in stage at diagnosis cannot explain inequalities in surgery. This 
concurs with results from our review on socioeconomic inequalities in lung cancer 
treatment, where the association between SEP and receipt of surgery was independent of 
stage at diagnosis. When receipt of treatment was examined in studies of early-stage patients 
only, low SEP remained associated with reduced likelihood of surgery (8).
Diagnostic delay has been implicated as a factor that contributes to the poorer survival of 
UK cancer patients compared to the European average (2). However, the impact of delay on 
lung cancer survival is unclear (60) and some studies suggest that those who experience 
shorter system delay may have poorer lung cancer survival as they are clinically “sicker”, 
with more obvious symptoms that result in urgent referral, diagnosis and treatment (1). More 
deprived patients have been shown to have higher comorbidity (34). A recent UK study, 
which found that lung cancer patients who were more clinically unwell were referred, 
diagnosed and treated more quickly, suggested that this ‘sicker quicker’ effect may act to 
effectively cancel out socio-economic related delays that might otherwise result in longer 
time intervals for more deprived patients (34). Very few of the studies included in this 
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current review took account of patient health status when examining time intervals and lack 
of control for this major confounder may mask any inequalities that are present.
Strengths and weaknesses of the review and of the available evidence
No previous reviews have systematically assessed socioeconomic inequalities in stage at 
diagnosis and in time intervals on the lung cancer care pathway and few have considered 
equity in a meta-analysis. Extensive searches were carried out to identify studies in the 
published literature. However, it is possible that not all relevant studies were obtained.
Although a number of studies examined stage at diagnosis, very few good quality studies 
examined comparable intervals on the lung cancer diagnostic and treatment pathway, 
meaning that meta-analysis was only possible for studies examining stage at diagnosis. The 
included studies reported observational data only. The suitability of meta-analysis for 
observational studies has been questioned, as it may produce precise but spurious results 
(61). Heterogeneity can be considered high at >50% (62). Study heterogeneity was taken 
into account. Separate analyses by healthcare system type were carried out and different 
effects were found.
There was population overlap between some datasets. We attempted to include only 
substantially non-overlapping datasets within the final meta-analysis to ensure independence 
of results. A judgement had to be made as to which was the best quality and most 
appropriate paper to include, but sensitivity analyses using different inclusion combinations 
(Appendix a) did not change the overall findings and nor did including all suitable studies, 
regardless of population overlap.
A number of different measures of SEP were used in included studies. These likely 
categorise different people, and different proportions of the population, into the most and 
least deprived groups, meaning that similar populations are not always being compared 
across studies. This is a recognised problem in equity reviews (8). Most UK studies employ 
deprivation-index measures of SEP, whereas US-based studies rely more on income-based 
measures. However, across all included cases, area-based measures of SEP were common. 
These may not accurately reflect individual-level circumstances (63) leading to error, and 
possible bias. This may mean we have under-estimated the strength of the true association 
between SEP and both stage and intervals. Many included studies used cohort or cancer 
registry data not specifically collected to study socio-economic inequalities, meaning that 
authors of studies included in the review were working with the best available data for 
secondary analysis. Effort should be made to ensure household, or individual-level, markers 
of SEP are included in cohort studies and cancer registry datasets to facilitate future 
analyses.
In the UK only around 20% of patients are diagnosed at an early stage and so the meta-
analysis may be underpowered to detect differences between early and late stage 
presentation by SEP.
In order to conduct meta-analysis it is necessary to compare the odds of advanced stage at 
diagnosis in the most versus the least deprived groups. This necessarily simplifies what may 
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be a complex relationship across SEP groups. The ORs used in the meta-analyses were not 
consistently adjusted for the same covariates. However, we attempted to take this into 
account in the quality scores and by conducting subgroup sensitivity analyses. Examining 
only high quality studies did not alter findings nor did other sensitivity analyses. It may be 
useful to develop clear guidance on what variables should and should not be adjusted for in 
future analyses to ensure comparability of findings.
Having been unable to find a suitable tool for assessing cohort study quality for a previous 
review, we created our own. Here we adapted our previously developed tool (8) to produce a 
unique tool that is highly specific to detect bias in the type of study included, considering 
representativeness of the sample, measure of independent and outcome variables and 
confounder adjustment. It is similar to a bias assessment checklist tool developed 
independently in the interim by another review group examining time to diagnosis and 
treatment in cancer (16).
Many of the studies included in the narrative review were not of high quality. Many studies 
used routine data which rely on accurate routine recording of dates and others included self-
report of time intervals, which may suffer from recall bias. There is a possibility of 
ascertainment bias where sicker patients may be less likely to have stage data recorded. The 
‘waiting time paradox’ where sicker patients progress more quickly through the care 
pathway as they appear more ill (1) was not well accounted for and this may mask any true 
socio-economic inequalities in time intervals (34). Lack of consideration of this is a major 
limitation in the included studies and makes it difficult to draw firm conclusions. Future 
investigators should routinely include adjustment for patient health status.
Publication bias is a possibility that needs to be considered for any systematic review, as 
studies reporting null findings may be less likely to be published or, if published, to report 
numerical outcomes (62). However, as the majority of the results reported for this review 
support the null hypothesis, further unreported null results would not change the findings.
Implications for policy and practice
No inequalities in the patient interval (from symptom recognition to presentation) or in stage 
at diagnosis were found in this review. There is no current evidence that more deprived 
patients wait longer to consult or present with later stage lung cancer. Therefore there is no 
indication that campaigns to improve early diagnosis need to be targeted at specific socio-
economic groups. Rather that these need to be aimed at everyone with symptoms that might 
potentially indicate lung cancer. However, as more deprived groups have a higher incidence 
of lung cancer it may still be prudent to target campaigns at these groups.
Results for the referral and diagnostic intervals were inconclusive but there was some 
suggestion of inequalities within these intervals. This could be indicative of clinical bias 
where, in countries with gatekeeping systems, primary care providers may be more actively 
referring more affluent patients. Alternatively, patient ability to navigate through the referral 
process may vary by SEP (34, 64).
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Future Research
Although reducing the time to diagnosis and treatment may have important psychological 
implications for all patients (16), evidence for socio-economic inequalities in time to 
treatment was not found. However, many studies did not take factors such as cancer stage 
and health status into account. Better quality studies that attempt to overcome the ‘sicker 
quicker’ effect by accounting for health status and examining early stage patients separately 
are required, to more clearly determine whether inequalities are present.
Socio-economic inequalities in stage at diagnosis have been suggested as an important 
explanatory factor for survival inequalities in cancer (2). However, socio-economic 
inequalities in stage at diagnosis for lung cancer were not found in UHCSs in the meta-
analysis conducted in this review and nor was there good evidence for inequalities in time 
spent on the care pathway. Previous research suggests that socio-economic inequalities in 
lung cancer treatment rather than in time to treatment might help explain socio-economic 
inequalities in lung cancer survival (10). Further investigation of the patient, tumour and 
system factors that are important determinants of treatment inequalities is required.
Conclusions
There is no clear evidence of socio-economic inequalities in stage at diagnosis or time spent 
within intervals on the symptom to treatment pathway for lung cancer. However, the quality 
of evidence available is significantly limited by the failure of most studies to adjust for 
important potential confounders. Results from this review would suggest that inequalities in 
time to treatment or in stage at diagnosis are unlikely to account for known socio-economic 
inequalities in receipt of treatment for, and survival from, lung cancer in UHCSs, but may be 
present in non-UHCSs.
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What is the key question?
Are there socio-economic inequalities in stage at diagnosis for lung cancer, and in the 
length of time spent on the lung cancer pathway from symptom onset to treatment?
What is the bottom line?
There was no evidence of socio-economic inequalities in late stage at diagnosis in the 
most, compared to the least, deprived group nor of inequalities in the patient or treatment 
intervals, and no consistent pattern was observed in diagnostic or referral intervals.
Why read on?
Socio-economic inequalities in stage at diagnosis are thought to be an important 
explanatory factor for survival inequalities in cancer. This is the first study to 
systematically explore the evidence for inequalities in stage at diagnosis for lung cancer.
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Figure 1. 
PRISMA flow diagram
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Figure 2. 
Likelihood of advanced stage at diagnosis in lowest compared to highest SEP group, by 
healthcare system and overall
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Figure 3. 
Summary of the review findings for each interval
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